INTRODUCTION This retrospective observational study included patients with T2DM who were switched from 1.0 mg of semaglutide to tirzepatide at our institution between April 2023 and November 2024
Gastrointestinal issues : Conditions such as Crohn's disease , Celiac disease , gastric bypass surgery , or other digestive disorders can impair B12 absorption
Clinical studies have shown that semaglutide can also contribute to improved cardiovascular outcomes, reducing the risk of major adverse cardiovascular events in patients with type 2 diabetes
This may indicate a need for dose adjustment
Several studies have demonstrated the anti-inflammatory, anti-oxidant and free radical scavenging properties of ALCAR, as well as its stabilizing effects on mitochondrial membrane [22]
Counsel patients explicitly, even when not hungry, that protein intake is non-negotiable